CN103906530B - 成纤维细胞生长因子21变体 - Google Patents

成纤维细胞生长因子21变体 Download PDF

Info

Publication number
CN103906530B
CN103906530B CN201280048530.2A CN201280048530A CN103906530B CN 103906530 B CN103906530 B CN 103906530B CN 201280048530 A CN201280048530 A CN 201280048530A CN 103906530 B CN103906530 B CN 103906530B
Authority
CN
China
Prior art keywords
fgf21
variant
seq
variants
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280048530.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN103906530A (zh
Inventor
C·D·迪金森
D·A·德赖弗
R·J·达林
M·D·贡西亚茨
R·米卡诺维克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46964112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103906530(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN103906530A publication Critical patent/CN103906530A/zh
Application granted granted Critical
Publication of CN103906530B publication Critical patent/CN103906530B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201280048530.2A 2011-10-04 2012-09-25 成纤维细胞生长因子21变体 Expired - Fee Related CN103906530B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161542906P 2011-10-04 2011-10-04
US61/542,906 2011-10-04
PCT/US2012/057053 WO2013052311A1 (en) 2011-10-04 2012-09-25 Fibroblast growth factor 21 variants

Publications (2)

Publication Number Publication Date
CN103906530A CN103906530A (zh) 2014-07-02
CN103906530B true CN103906530B (zh) 2016-01-20

Family

ID=46964112

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280048530.2A Expired - Fee Related CN103906530B (zh) 2011-10-04 2012-09-25 成纤维细胞生长因子21变体

Country Status (28)

Country Link
US (2) US8541369B2 (https=)
EP (1) EP2763689B1 (https=)
JP (1) JP6060167B2 (https=)
KR (1) KR20140059271A (https=)
CN (1) CN103906530B (https=)
AP (1) AP2014007532A0 (https=)
AR (1) AR087973A1 (https=)
AU (1) AU2012318956A1 (https=)
BR (1) BR112014007532A2 (https=)
CA (1) CA2843520A1 (https=)
CL (1) CL2014000801A1 (https=)
CO (1) CO6910165A2 (https=)
CR (1) CR20140142A (https=)
DO (1) DOP2014000050A (https=)
EA (1) EA201490521A1 (https=)
EC (1) ECSP14013285A (https=)
ES (1) ES2548214T3 (https=)
IL (1) IL230754A0 (https=)
IN (1) IN2014CN00782A (https=)
MA (1) MA35458B1 (https=)
MX (1) MX2014004159A (https=)
PE (1) PE20142044A1 (https=)
PH (1) PH12014500740A1 (https=)
SG (1) SG11201401792UA (https=)
TN (1) TN2014000096A1 (https=)
TW (1) TWI461435B (https=)
WO (1) WO2013052311A1 (https=)
ZA (1) ZA201400882B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
CN105601748B (zh) 2011-07-01 2021-08-27 恩格姆生物制药公司 用于代谢病症和疾病治疗的组合物、应用和方法
MA37506B1 (fr) * 2012-05-15 2017-03-31 Lilly Co Eli Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21
CA2871656A1 (en) 2012-06-11 2013-12-19 Eli Lilly And Company Fibroblast growth factor 21 variants
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
HK1214832A1 (zh) 2012-11-28 2016-08-05 恩格姆生物制药公司 用於代謝病症和疾病治療的組合物和方法
ES2915851T3 (es) 2012-12-27 2022-06-27 Ngm Biopharmaceuticals Inc Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CA2927592C (en) 2013-10-28 2020-08-18 Ngm Biopharmaceuticals, Inc. Fgf-19 variants for treating a fgf-19 dependent cancer or tumor
PE20170256A1 (es) 2014-01-24 2017-04-22 Ngm Biopharmaceuticals Inc Proteinas de union y sus metodos de uso
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
RU2729161C2 (ru) 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
WO2017220706A1 (en) * 2016-06-22 2017-12-28 Novo Nordisk A/S Pharmaceutical compositions of fgf21 derivatives and uses thereof
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN106432509B (zh) * 2016-09-13 2019-05-21 河南师范大学 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用
CN106220724B (zh) * 2016-09-13 2019-10-11 河南师范大学 人成纤维细胞生长因子21重组蛋白及其制备方法和应用
CN106397607A (zh) * 2016-09-13 2017-02-15 河南师范大学 重组人成纤维细胞生长因子21融合蛋白及其在制备治疗代谢疾病药物中的应用
WO2018166461A1 (en) 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
SG11202001379WA (en) 2017-09-08 2020-03-30 Bristol Myers Squibb Co Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
WO2019123427A1 (en) 2017-12-22 2019-06-27 Novartis Ag Methods of treating metabolic disorders with fgf21 variants
AU2019218147B2 (en) * 2018-02-08 2023-06-08 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
KR20210027426A (ko) * 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 Fgf21 제제
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
EP3935075A4 (en) 2019-03-05 2023-01-18 Sunshine Lake Pharma Co., Ltd. POLYPEPTIDE MOLECULE AND APPLICATION THEREOF
CN111944055B (zh) 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
EP4087612A1 (en) 2020-01-08 2022-11-16 Bristol-Myers Squibb Company Fgf-21 conjugate formulations
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
JP2023538533A (ja) 2020-08-07 2023-09-08 ブリストル－マイヤーズ スクイブ カンパニー 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
KR102495299B1 (ko) * 2020-11-03 2023-02-06 토드제약 주식회사 Fgf21의 열탄력성을 이용한 fgf21 생산 방법
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases
WO2023284822A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1890371A (zh) * 2003-12-10 2007-01-03 伊莱利利公司 成纤维细胞生长因子的21突变蛋白
CN101010338A (zh) * 2004-09-02 2007-08-01 伊莱利利公司 成纤维细胞生长因子21的突变蛋白
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
CN102143758A (zh) * 2008-06-04 2011-08-03 安姆根有限公司 Fgf21突变体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
US7622445B2 (en) 2004-09-02 2009-11-24 Eli Lilly And Company Muteins of fibroblast growth factor 21
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2010129503A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1890371A (zh) * 2003-12-10 2007-01-03 伊莱利利公司 成纤维细胞生长因子的21突变蛋白
CN101010338A (zh) * 2004-09-02 2007-08-01 伊莱利利公司 成纤维细胞生长因子21的突变蛋白
CN102143758A (zh) * 2008-06-04 2011-08-03 安姆根有限公司 Fgf21突变体及其用途
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
定点突变FGF21提高表达量研究;李德山等;《东北农业大学学报》;20130331;第44卷(第3期);83-88 *

Also Published As

Publication number Publication date
MX2014004159A (es) 2015-02-12
SG11201401792UA (en) 2014-08-28
US20130085098A1 (en) 2013-04-04
AU2012318956A1 (en) 2014-02-06
DOP2014000050A (es) 2014-04-15
JP2014530220A (ja) 2014-11-17
KR20140059271A (ko) 2014-05-15
CL2014000801A1 (es) 2014-09-12
CA2843520A1 (en) 2013-04-11
IL230754A0 (en) 2014-03-31
AR087973A1 (es) 2014-04-30
CO6910165A2 (es) 2014-03-31
US20130324460A1 (en) 2013-12-05
EP2763689B1 (en) 2015-08-12
EA201490521A1 (ru) 2014-07-30
MA35458B1 (fr) 2014-09-01
TW201326198A (zh) 2013-07-01
ES2548214T3 (es) 2015-10-14
PE20142044A1 (es) 2014-12-06
PH12014500740A1 (en) 2020-10-19
JP6060167B2 (ja) 2017-01-11
CR20140142A (es) 2014-05-02
US8541369B2 (en) 2013-09-24
AP2014007532A0 (en) 2014-03-31
ECSP14013285A (es) 2014-05-31
US8883726B2 (en) 2014-11-11
CN103906530A (zh) 2014-07-02
IN2014CN00782A (https=) 2015-04-03
ZA201400882B (en) 2016-02-24
EP2763689A1 (en) 2014-08-13
TN2014000096A1 (en) 2015-07-01
TWI461435B (zh) 2014-11-21
BR112014007532A2 (pt) 2017-04-04
WO2013052311A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
CN103906530B (zh) 成纤维细胞生长因子21变体
CN104364261B (zh) 成纤维细胞生长因子21变体
CN104394882B (zh) 成纤维细胞生长因子21蛋白
CN1346369B (zh) 用于预防和治疗贫血的方法以及组合物
JP2007531715A (ja) グリコール結合ｆｇｆ−２１化合物
WO2014149699A1 (en) Bifunctional protein
EP4059512A1 (en) Aqueous pharmaceutical composition containing fusion protein of serum albumin and growth hormone
EP4047006A1 (en) Method for producing fusion protein of serum albumin and growth hormone

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160120

Termination date: 20180925